.2
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SECOND QUARTER
2009
EQUITY INCOME FROM AFFILIATES (millions of dollars)
| 2Q ’09 | 2Q ’08 | YTD 2009 | YTD 2008 | |||||||||
| MERCK / SCHERING-PLOUGH |
$ | 362.3 | $ | 365.2 | $ | 653.2 | $ | 758.0 | ||||
| ASTRAZENECA LP |
122.9 | 61.4 | 291.2 | 192.5 | ||||||||
| Other (1) |
101.9 | 96.4 | 228.6 | 224.6 | ||||||||
| TOTAL |
$ | 587.1 | $ | 523.0 | $ | 1,173.0 | $ | 1,175.1 | ||||
| (1) | Primarily reflects results for Merial Limited, Sanofi Pasteur MSD and Johnson & Johnson°Merck Consumer Pharmaceuticals. |
JOINT VENTURE SALES DETAIL (millions of dollars)
All sales reported here are end-market JV sales, presented on a “NET” basis.
| Merial |
2Q ’09 | 2Q ’08 | YTD 2009 | YTD 2008 | ||||||||
| FRONTLINE, other fipronil |
$ | 279.5 | $ | 306.1 | $ | 586.4 | $ | 647.7 | ||||
| BIOLOGICALS |
188.2 | 208.5 | 360.1 | 382.9 | ||||||||
| IVOMEC, HEARTGARD, other avermectins |
115.4 | 140.3 | 250.1 | 286.4 | ||||||||
| Other Animal Health |
68.1 | 77.2 | 138.7 | 148.7 | ||||||||
| TOTAL MERIAL SALES |
$ | 651.2 | $ | 732.1 | $ | 1,335.3 | $ | 1,465.7 | ||||
| Sanofi Pasteur MSD |
2Q ’09 | 2Q ’08 | YTD 2009 | YTD 2008 | ||||||||
| GARDASIL |
$ | 144.9 | $ | 234.2 | $ | 309.0 | $ | 474.0 | ||||
| OTHER VIRAL VACCINES |
26.9 | 29.1 | 52.3 | 51.8 | ||||||||
| HEPATITIS VACCINES |
11.0 | 19.4 | 24.4 | 37.4 | ||||||||
| ROTATEQ |
10.1 | 7.3 | 18.8 | 13.3 | ||||||||
| Other Vaccines |
120.3 | 140.0 | 252.0 | 264.9 | ||||||||
| TOTAL SANOFI PASTEUR MSD SALES |
$ | 313.2 | $ | 430.0 | $ | 656.5 | $ | 841.4 | ||||
| Merck / Schering-Plough Collaboration |
2Q ’09 | 2Q ’08 | YTD 2009 | YTD 2008 | ||||||||
| VYTORIN |
$ | 519.9 | $ | 592.1 | $ | 985.9 | $ | 1,243.3 | ||||
| ZETIA |
513.5 | 560.4 | 992.8 | 1,142.1 | ||||||||
| TOTAL MERCK / SCHERING-PLOUGH SALES |
$ | 1,033.4 | $ | 1,152.5 | $ | 1,978.7 | $ | 2,385.4 | ||||
OTHER (INCOME) EXPENSE, NET (millions of dollars)
| 2Q ’09 | 2Q ’08 | YTD 2009 | YTD 2008 | |||||||||||||
| INTEREST INCOME |
$ | (70.0 | ) | $ | (143.4 | ) | $ | (166.3 | ) | $ | (313.0 | ) | ||||
| INTEREST EXPENSE |
99.5 | 50.6 | 160.2 | 123.2 | ||||||||||||
| EXCHANGE (GAINS) LOSSES |
(20.0 | ) | 8.7 | (3.5 | ) | 21.3 | ||||||||||
| Other, net (1) |
(5.9 | ) | (28.7 | ) | (54.0 | ) | (2,153.5 | ) | ||||||||
| TOTAL |
$ | 3.6 | $ | (112.8 | ) | $ | (63.6 | ) | $ | (2,322.0 | ) | |||||
| (1) | Other, net in the first six months of 2008 primarily reflects a $2.2 billion gain on distribution from AstraZeneca LP. |
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SECOND QUARTER
2009
NET PRODUCT SALES DETAIL (millions of dollars)
| 2Q ’09 vs. 2Q ’08 | ||||||||||||||||||
| PRODUCT |
TOTAL % CHG |
TOTAL $ |
U.S. % CHG |
U.S. $ |
Foreign % CHG |
Foreign $ | ||||||||||||
| COZAAR / HYZAAR |
-4 | % | 906 | 5 | % | 332 | -8 | % | 573 | |||||||||
| JANUVIA |
38 | % | 462 | 33 | % | 348 | 59 | % | 115 | |||||||||
| JANUMET |
* | 155 | 68 | % | 113 | * | 41 | |||||||||||
| SINGULAIR |
16 | % | 1,257 | 16 | % | 823 | 17 | % | 434 | |||||||||
| Vaccines: |
||||||||||||||||||
| GARDASIL |
-18 | % | 268 | -28 | % | 184 | 18 | % | 84 | |||||||||
| ROTATEQ |
-29 | % | 126 | -35 | % | 107 | 58 | % | 18 | |||||||||
| ZOSTAVAX |
-36 | % | 42 | -36 | % | 42 | N/A | — | ||||||||||
| OTHER VIRAL VACCINES (1) |
1 | % | 322 | 4 | % | 303 | -27 | % | 19 | |||||||||
| HEPATITIS VACCINES (2) |
-24 | % | 29 | -14 | % | 25 | -56 | % | 4 | |||||||||
| OTHER VACCINES (3) |
-24 | % | 53 | -9 | % | 30 | -37 | % | 23 | |||||||||
| Other Reported Products: |
||||||||||||||||||
| ARCOXIA |
-15 | % | 88 | N/A | — | -15 | % | 88 | ||||||||||
| CANCIDAS |
-7 | % | 149 | -29 | % | 18 | -3 | % | 130 | |||||||||
| COSOPT / TRUSOPT |
-43 | % | 125 | -87 | % | 11 | -13 | % | 114 | |||||||||
| CRIXIVAN / STOCRIN |
-30 | % | 56 | -12 | % | 3 | -30 | % | 53 | |||||||||
| EMEND |
17 | % | 77 | 26 | % | 51 | 3 | % | 26 | |||||||||
| FOSAMAX |
-33 | % | 277 | -66 | % | 42 | -18 | % | 236 | |||||||||
| INVANZ |
— | 71 | 9 | % | 37 | -8 | % | 34 | ||||||||||
| ISENTRESS |
* | 172 | 95 | % | 88 | * | 85 | |||||||||||
| MAXALT |
8 | % | 141 | 15 | % | 99 | -6 | % | 42 | |||||||||
| PRIMAXIN |
-21 | % | 160 | -23 | % | 32 | -20 | % | 128 | |||||||||
| PROPECIA |
-2 | % | 106 | -2 | % | 37 | -1 | % | 69 | |||||||||
| PROSCAR |
-8 | % | 79 | -59 | % | 1 | -6 | % | 78 | |||||||||
| TIMOPTIC / TIMOPTIC XE |
-15 | % | 27 | * | — | -9 | % | 27 | ||||||||||
| VASOTEC / VASERETIC |
-19 | % | 76 | N/A | — | -19 | % | 76 | ||||||||||
| ZOCOR |
-20 | % | 141 | -53 | % | 9 | -16 | % | 132 | |||||||||
| ZOLINZA |
46 | % | 4 | 48 | % | 4 | 19 | % | — | |||||||||
* 100% or over
N/A - Not Applicable
(1) - Includes ProQuad, M-M-R II and Varivax.
(2) - Includes Recombivax and Vaqta
(3) - Includes Pneumovax, Comvax and Pedvaxhib
TOTAL SALES: VOLUME, PRICE, EXCHANGE
| 2Q ’09 | % CHG | VOL | PX | FX | ||||||||
| TOTAL PHARMACEUTICAL SALES |
$ | 5,900 | -3 | % | 1 | 2 | -5 | |||||
| U.S. ($ MM) |
3,251 | -3 | % | -7 | 5 | N/A | ||||||
| Foreign ($ MM) |
2,649 | -2 | % | 11 | -2 | -11 | ||||||
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
JUNE YEAR-TO-DATE
2009
NET PRODUCT SALES DETAIL (millions of dollars)
| JUNE YTD ’09 vs. JUNE YTD ’08 | |||||||||||||||
| TOTAL % CHG |
TOTAL $ |
U.S. % CHG |
U.S. $ |
Foreign % CHG |
Foreign $ | ||||||||||
| PRODUCT |
|||||||||||||||
| COZAAR / HYZAAR |
-2 | % | 1,745 | 4 | % | 636 | -6 | % | 1,109 | ||||||
| JANUVIA |
44 | % | 873 | 35 | % | 661 | 83 | % | 213 | ||||||
| JANUMET |
* | 283 | 75 | % | 214 | * | 69 | ||||||||
| SINGULAIR |
6 | % | 2,315 | 6 | % | 1,505 | 6 | % | 809 | ||||||
| Vaccines: |
|||||||||||||||
| GARDASIL |
-26 | % | 530 | -34 | % | 363 | -1 | % | 167 | ||||||
| ROTATEQ |
-29 | % | 260 | -33 | % | 232 | 26 | % | 28 | ||||||
| ZOSTAVAX |
-16 | % | 118 | -16 | % | 118 | N/A | — | |||||||
| OTHER VIRAL VACCINES (1) |
6 | % | 574 | 9 | % | 538 | -28 | % | 37 | ||||||
| HEPATITIS VACCINES (2) |
-12 | % | 63 | — | 53 | -46 | % | 10 | |||||||
| OTHER VACCINES (3) |
-24 | % | 108 | -4 | % | 60 | -39 | % | 49 | ||||||
| Other Reported Products: |
|||||||||||||||
| ARCOXIA |
-14 | % | 169 | N/A | — | -14 | % | 169 | |||||||
| CANCIDAS |
-7 | % | 287 | -34 | % | 37 | -1 | % | 250 | ||||||
| COSOPT / TRUSOPT |
-41 | % | 246 | -85 | % | 25 | -12 | % | 221 | ||||||
| CRIXIVAN / STOCRIN |
-32 | % | 105 | -18 | % | 6 | -33 | % | 99 | ||||||
| EMEND |
17 | % | 146 | 18 | % | 95 | 15 | % | 51 | ||||||
| FOSAMAX |
-39 | % | 539 | -75 | % | 82 | -18 | % | 456 | ||||||
| INVANZ |
5 | % | 132 | 12 | % | 70 | -2 | % | 62 | ||||||
| ISENTRESS |
* | 320 | * | 163 | * | 158 | |||||||||
| MAXALT |
9 | % | 274 | 16 | % | 191 | -5 | % | 83 | ||||||
| PRIMAXIN |
-20 | % | 324 | -33 | % | 62 | -16 | % | 262 | ||||||
| PROPECIA |
-2 | % | 209 | -3 | % | 73 | -1 | % | 136 | ||||||
| PROSCAR |
-12 | % | 151 | -57 | % | 3 | -10 | % | 149 | ||||||
| TIMOPTIC / TIMOPTIC XE |
-10 | % | 55 | -86 | % | 1 | -5 | % | 54 | ||||||
| VASOTEC / VASERETIC |
-19 | % | 153 | N/A | — | -19 | % | 153 | |||||||
| ZOCOR |
-22 | % | 278 | -63 | % | 18 | -15 | % | 261 | ||||||
| ZOLINZA |
28 | % | 9 | 30 | % | 8 | 6 | % | 1 | ||||||
* 100% or over
N/A - Not Applicable
(1) - Includes ProQuad, M-M-R II and Varivax.
(2) - Includes Recombivax and Vaqta
(3) - Includes Pneumovax, Comvax and Pedvaxhib
TOTAL SALES: VOLUME, PRICE, EXCHANGE
| JUN YTD ’09 | % CHG | VOL | PX | FX | ||||||||
| TOTAL PHARMACEUTICAL SALES |
$ | 11,285 | -5 | % | -2 | 2 | -4 | |||||
| U.S. ($ MM) |
6,207 | -6 | % | -11 | 5 | N/A | ||||||
| Foreign ($ MM) |
5,078 | -3 | % | 8 | -2 | -9 | ||||||